Utah Medical Products (NASDAQ:UTMD) Receives Daily News Impact Score of 0.05

News articles about Utah Medical Products (NASDAQ:UTMD) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Utah Medical Products earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the medical instruments supplier an impact score of 47.8849724281288 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s analysis:

UTMD stock traded up $0.35 during trading on Tuesday, reaching $101.00. 5,600 shares of the company were exchanged, compared to its average volume of 15,189. The company has a market cap of $387.60 million, a P/E ratio of 25.65 and a beta of 0.61. Utah Medical Products has a 52-week low of $101.45 and a 52-week high of $101.45.

Utah Medical Products (NASDAQ:UTMD) last posted its quarterly earnings data on Thursday, April 26th. The medical instruments supplier reported $1.09 earnings per share for the quarter. The business had revenue of $10.89 million during the quarter. Utah Medical Products had a net margin of 21.56% and a return on equity of 18.94%.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 6th. Stockholders of record on Friday, June 15th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, June 14th.

UTMD has been the topic of a number of recent research reports. ValuEngine upgraded shares of Utah Medical Products from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. BidaskClub lowered shares of Utah Medical Products from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 28th.

In other news, CEO Kevin L. Cornwell sold 7,034 shares of the company’s stock in a transaction on Thursday, March 8th. The shares were sold at an average price of $91.93, for a total value of $646,635.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barbara A. Payne sold 2,406 shares of the company’s stock in a transaction on Monday, May 7th. The shares were sold at an average price of $104.56, for a total transaction of $251,571.36. Following the completion of the transaction, the director now owns 26,432 shares of the company’s stock, valued at $2,763,729.92. The disclosure for this sale can be found here. Insiders sold 20,447 shares of company stock valued at $1,938,873 in the last three months. Company insiders own 8.80% of the company’s stock.

About Utah Medical Products

Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD, an infant respiratory hood; and DELTRAN PLUS, a blood pressure monitoring system.

Insider Buying and Selling by Quarter for Utah Medical Products (NASDAQ:UTMD)

Receive News & Ratings for Utah Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Utah Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply